Pharmaceutical firms Avexima Innotech and Avexima Diol have become the first residents of the Innovative Science and Technology Center (INTC) on Russky Island in Vladivostok, as announced by Presidential Envoy to the Far Eastern Federal District Yuri Trutnev, according to a TASS report.
“As part of the Eastern Economic Forum, we are launching the first pilot building, which will host the first residents, Avexima Innotech and Avexima Diol, full-cycle pharmaceutical companies focused on creating import-substituting domestically produced drugs,” Trutnev said.
Avexima Diol has already launched a pilot production line for the first Russian antithrombotic drug, Dimolegin. According to Denis Remenyako, General Director of the company, the Avexima Diol research center is also opening on the pilot site — a 500-square-meter laboratory equipped with the most modern equipment. The project received investments totaling over 150 million rubles. Remenyako stated that the company aims to develop at least 10 drugs and introduce them into industrial production within the next three years.
Innovative Science and Technology Center (ISTC) is a special zone offering preferential conditions for innovative enterprises. The pilot site is expected to attract 25.5 billion rubles in investment and create 4,500 jobs, the press service of the plenipotentiary reported. It is planned that by 2036, the center will bring together over 250 technology companies, with its products entering the markets of Russia, the Asia-Pacific region, and BRICS countries under the brand “Made in Russky.” Preliminary estimates suggest the combined revenue of ISTC residents will exceed 1.5 billion rubles within five years.
